Full Title
A Phase I Study of Concurrent Abemaciclib and Radiation Therapy (RT) for Patients with Metastatic Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Breast CancerPurpose
Researchers want to find the best dose of abemaciclib to combine with radiation therapy to treat advanced breast cancer. The people in this study have metastatic breast cancer that is fueled by estrogen or progesterone (hormone receptor-positive cancer). In addition, their breast cancer does not make a protein called HER2.
Combining abemaciclib and radiation therapy at the same time may work better than the standard approach. The standard treatment involves stopping abemaciclib until after radiation therapy is completed.
Abemaciclib is a drug for advanced breast cancer that blocks proteins called CDKs. CDKs are involved in cancer growth. Abemaciclib is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have metastatic hormone receptor-positive HER2-negative breast cancer.
- Be planning to receive radiation therapy to treat cancer that spread to the bone.
- Have had no prior radiation therapy to the site of bone metastasis.
- Have completed prior chemotherapy at least 3 weeks before getting the study treatment.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Lior Braunstein’s office at 201-775-7446.